Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Here's a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga's Analyst Stock Ratings.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Premier, Inc. (NASDAQ: PINC)

• Dividend Yield: 3.03%
• Baird analyst Eric Coldwell downgraded the stock from Outperform to Neutral and cut the price target from $43 to $30 on May 3, 2023. This analyst has an accuracy rate of 66%.
• Raymond James analyst John Ransom downgraded the stock from Outperform to Market Perform on May 3, 2023. This analyst has an accuracy rate of 75%.
• Recent News: Premier recently announced that it will divest its non-healthcare GPO operations for approximately $800 million.

CVS Health Corporation (NYSE: CVS)

• Dividend Yield: 3.23%
• Wells Fargo analyst Stephen Baxter maintained an Equal-Weight rating and cut the price target from $95 to $76 on May 8, 2023. This analyst has an accuracy rate of 61%.
• Bernstein analyst Lance Wilkes maintained a Market Perform rating and cut the price target from $107 to $93 on May 2, 2023. This analyst has an accuracy rate of 66%.
• Recent News: CVS Health reported better-than-expected second-quarter financial results and issued FY23 guidance.

Medtronic plc (NYSE: MDT)

• Dividend Yield: 3.33%
• Baird analyst David Rescott initiated coverage on the stock with a Neutral rating and a price target of $90 on July 19, 2023. This analyst has an accuracy rate of 65%.
• Truist Securities analyst Richard Newitter maintained a Hold rating and cut the price target from $93 to $90 on May 26, 2023. This analyst has an accuracy rate of 78%.
• Recent News: Medtronic recalled certain implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) with glassed feedthrough.

Read More: Investor Optimism Falls Ahead Of Inflation Data